Lixte Biotechnology Holdings, Inc. LIXTW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

28/100

0/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Lixte Biotechnology Holdings, Inc. (LIXTW) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — LIXTW

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-1.26

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-2.68	$0.00	$-2.13M	-
2017	$-1.94	$0.00	$-1.81M	-
2018	$-2.18	$0.00	$-2.13M	-
2019	$-2.20	$0.00	$-2.39M	-
2020	$-2.89	$0.00	$-3.26M	-
2021	$-5.00	$0.00	$-6.73M	-
2022	$-4.00	$0.00	$-6.31M	-
2023	$-2.66	$0.00	$-5.09M	-
2024	$-1.59	$0.00	$-3.59M	-
2025	$-1.26	$0.00	$-6.08B	-